Informations générales (source: ClinicalTrials.gov)
CANPOS: Predictive Biomarkers of Tumor Progression in Non-small Cell Lung Cancer (CANPOS)
Observational
Hospices Civils de Lyon (Voir sur ClinicalTrials)
novembre 2013
décembre 2025
29 juin 2024
CANPOS is a non-interventional study aiming at evaluate at the time of initial surgery
the value of new serum markers to predict the occurrence of metastases in patients with
early-stage non-small cell lung cancer. This would represent a rational to develop
personalized follow-up and prevention strategies
Etablissements
| Les établissements hors Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| Hospices Civils de Lyon / Hôpital Neurologique Pierre Wertheimer - 69500 - Bron - France | Nicolas Girard | Contact (sur clinicalTrials) | |||
Critères
Tous
Inclusion Criteria:
- patients with a diagnosis or suspected for a diagnosis of lung cancer, non-small
cell lung cancer
- age over 18 years
- patient naïve of any oncology treatment (excluding surgery alone) within the past 5
years
- patient who signed the informed consent by the study protocol
Exclusion criteria were:
- any ongoing treatment for cancer
- any history of cancer within 5 years before the diagnosis of lung cancer
- any psychological, sociological or geographical conditions that would not allow the
study follow-up
- patients with a diagnosis or suspected for a diagnosis of lung cancer, non-small
cell lung cancer
- age over 18 years
- patient naïve of any oncology treatment (excluding surgery alone) within the past 5
years
- patient who signed the informed consent by the study protocol
Exclusion criteria were:
- any ongoing treatment for cancer
- any history of cancer within 5 years before the diagnosis of lung cancer
- any psychological, sociological or geographical conditions that would not allow the
study follow-up